NAD+ declines with age, and supplementation with precursors such as nicotinamide riboside and nicotinamide mononucleotide reliably raises NAD+ concentrations in blood — by roughly 50% to 140% depending on dose and compound. Whether this translates into higher NAD+ in muscle and organs, or into measurable functional benefit, remains unresolved, with human trials producing far weaker results than animal models. The gap between a shifted biomarker and an improved outcome defines the current state of the evidence.
Key Points
- NR and NMN raise blood NAD+ substantially in controlled human trials
- Tissue-level uptake and functional benefits remain unconfirmed in humans
- Oral NAD+ itself degrades in digestion; liposomal data preliminary
Longevity Analysis
NAD+ sits at the center of cellular energy conversion, DNA repair and mitochondrial maintenance, which explains why its age-related decline attracts attention — and why a rising blood marker is a poor substitute for demonstrated repair capacity or physical performance. Much of the decline is driven by accumulated DNA damage and inflammation-sensitive enzymes like CD38, meaning the upstream drivers of depletion deserve as much attention as the downstream replenishment. Precursor supplementation is a reasonable additive strategy only once the inflammatory and metabolic load accelerating NAD+ consumption has been addressed, and its value should be judged by function and recovery over time rather than by a single biomarker.
Original published by The Conversation - Longevity, by Justin Roberts, Professor of Nutritional Physiology, Anglia Ruskin University.